The association of adequate empirical treatment and time to recovery from bacteraemic urinary tract infections: a retrospective cohort study.


Journal

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
ISSN: 1469-0691
Titre abrégé: Clin Microbiol Infect
Pays: England
ID NLM: 9516420

Informations de publication

Date de publication:
Oct 2019
Historique:
received: 04 10 2018
revised: 14 02 2019
accepted: 23 02 2019
pubmed: 8 3 2019
medline: 9 1 2020
entrez: 8 3 2019
Statut: ppublish

Résumé

Our objective was to evaluate whether patients with bacteraemic urinary tract infection (UTI) who receive inadequate empirical therapy have worse outcomes than those with adequate therapy. This was a retrospective cohort study of patients with bacteraemic UTI. The exposure variable was adequate versus inadequate empirical antibiotic therapy (AEAT versus IEAT) within 24 h of culture collection. Primary endpoint was time to cure. The primary analysis used propensity score models with inverse probability of treatment weights. A secondary Cox proportional hazards modelling approach was used to test the robustness of this finding, and to evaluate other patient and pathogen predictors of time to cure. Of 469 patients with bacteraemic UTI, 368 (78.5%) received AEAT. There was no significant difference in mortality between those receiving AEAT and those receiving IEAT (adjusted OR 0.86, 95%CI 0.47-1.58). Receipt of AEAT had no association with time to cure (HR 0.93, 95%CI 0.73-1.19, p 0.55) or time to normalization of individual clinical variables. Cox proportional hazards modelling revealed that longer time to cure was associated with liver disease (HR 0.25, 95%CI 0.08-0.76, p 0.015), prior stroke (HR 0.73, 95%CI 0.54-0.99, p 0.044), empirical receipt of piperacillin-tazobactam (HR 0.77, 95%CI 0.59-0.99, p 0.044), qSOFA score >1 (HR 0.68, 95%CI 0.55-0.84, p < 0.001), and hospital-onset UTI (HR 0.53, 95%CI 0.39-0.71, p < 0.001). In conclusion, we found no association between AEAT and time to cure for patients with bacteraemic UTI. It may be appropriate to accept a higher risk threshold when choosing empirical antibiotic regimens, even in centres with high rates of resistant uropathogens.

Identifiants

pubmed: 30844435
pii: S1198-743X(19)30095-3
doi: 10.1016/j.cmi.2019.02.027
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1253-1258

Informations de copyright

Copyright © 2019 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Auteurs

J B Wiggers (JB)

Division of Infectious Diseases, University of Toronto, Toronto, Ontario, Canada.

P Sehgal (P)

Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

R Pinto (R)

Department of Critical Care Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.

D MacFadden (D)

Division of Infectious Diseases, University of Toronto, Toronto, Ontario, Canada.

N Daneman (N)

Division of Infectious Diseases, University of Toronto, Toronto, Ontario, Canada; Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Division of Infectious Diseases, Sunnybrook Health Sciences Centre, Toronto, Ontario Canada. Electronic address: Nick.Daneman@sunnybrook.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH